-
Something wrong with this record ?
Glycopolymers Decorated with 3-O-Substituted Thiodigalactosides as Potent Multivalent Inhibitors of Galectin-3
D. Vrbata, M. Filipová, MR. Tavares, J. Červený, M. Vlachová, M. Šírová, H. Pelantová, L. Petrásková, L. Bumba, R. Konefał, T. Etrych, V. Křen, P. Chytil, P. Bojarová
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Galectin 3 * metabolism MeSH
- Prospective Studies MeSH
- Thiogalactosides * pharmacology MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Galectin-3 (Gal-3) participates in many cancer-related metabolic processes. The inhibition of overexpressed Gal-3 by, e.g., β-galactoside-derived inhibitors is hence promising for cancer treatment. The multivalent presentation of such inhibitors on a suitable biocompatible carrier can enhance the overall affinity to Gal-3 and favorably modify the interaction with Gal-3-overexpressing cells. We synthesized a library of C-3 aryl-substituted thiodigalactoside inhibitors and their multivalent N-(2-hydroxypropyl)methacrylamide (HPMA)-based counterparts with two different glycomimetic contents. Glycopolymers with a higher content of glycomimetic exhibited a higher affinity to Gal-3 as assessed by ELISA and biolayer interferometry. Among them, four candidates (with 4-acetophenyl, 4-cyanophenyl, 4-fluorophenyl, and thiophen-3-yl substitution) were selected for further evaluation in cancer-related experiments in cell cultures. These glycopolymers inhibited Gal-3-induced processes in cancer cells. The cyanophenyl-substituted glycopolymer exhibited the strongest antiproliferative, antimigratory, antiangiogenic, and immunoprotective properties. The prepared glycopolymers appear to be prospective modulators of the tumor microenvironment applicable in the therapy of Gal-3-associated cancers.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019204
- 003
- CZ-PrNML
- 005
- 20220804135433.0
- 007
- ta
- 008
- 220720s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jmedchem.1c01625 $2 doi
- 035 __
- $a (PubMed)35157467
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vrbata, David $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 20 Prague 4, Czech Republic
- 245 10
- $a Glycopolymers Decorated with 3-O-Substituted Thiodigalactosides as Potent Multivalent Inhibitors of Galectin-3 / $c D. Vrbata, M. Filipová, MR. Tavares, J. Červený, M. Vlachová, M. Šírová, H. Pelantová, L. Petrásková, L. Bumba, R. Konefał, T. Etrych, V. Křen, P. Chytil, P. Bojarová
- 520 9_
- $a Galectin-3 (Gal-3) participates in many cancer-related metabolic processes. The inhibition of overexpressed Gal-3 by, e.g., β-galactoside-derived inhibitors is hence promising for cancer treatment. The multivalent presentation of such inhibitors on a suitable biocompatible carrier can enhance the overall affinity to Gal-3 and favorably modify the interaction with Gal-3-overexpressing cells. We synthesized a library of C-3 aryl-substituted thiodigalactoside inhibitors and their multivalent N-(2-hydroxypropyl)methacrylamide (HPMA)-based counterparts with two different glycomimetic contents. Glycopolymers with a higher content of glycomimetic exhibited a higher affinity to Gal-3 as assessed by ELISA and biolayer interferometry. Among them, four candidates (with 4-acetophenyl, 4-cyanophenyl, 4-fluorophenyl, and thiophen-3-yl substitution) were selected for further evaluation in cancer-related experiments in cell cultures. These glycopolymers inhibited Gal-3-induced processes in cancer cells. The cyanophenyl-substituted glycopolymer exhibited the strongest antiproliferative, antimigratory, antiangiogenic, and immunoprotective properties. The prepared glycopolymers appear to be prospective modulators of the tumor microenvironment applicable in the therapy of Gal-3-associated cancers.
- 650 12
- $a galektin 3 $x metabolismus $7 D037502
- 650 _2
- $a prospektivní studie $7 D011446
- 650 12
- $a thiogalaktosidy $x farmakologie $7 D013862
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Filipová, Marcela $u Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského nám. 2, CZ-162 06 Prague 6, Czech Republic $1 https://orcid.org/0000000335037973
- 700 1_
- $a Tavares, Marina R $u Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského nám. 2, CZ-162 06 Prague 6, Czech Republic
- 700 1_
- $a Červený, Jakub $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 20 Prague 4, Czech Republic $u Department of Analytical Chemistry, Faculty of Science, Charles University, Albertov 6, CZ-128 43 Prague 2, Czech Republic
- 700 1_
- $a Vlachová, Miluše $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 20 Prague 4, Czech Republic
- 700 1_
- $a Šírová, Milada $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 20 Prague 4, Czech Republic
- 700 1_
- $a Pelantová, Helena $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 20 Prague 4, Czech Republic
- 700 1_
- $a Petrásková, Lucie $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 20 Prague 4, Czech Republic $1 https://orcid.org/0000000270525115 $7 xx0101789
- 700 1_
- $a Bumba, Ladislav $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 20 Prague 4, Czech Republic
- 700 1_
- $a Konefał, Rafał $u Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského nám. 2, CZ-162 06 Prague 6, Czech Republic
- 700 1_
- $a Etrych, Tomáš $u Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského nám. 2, CZ-162 06 Prague 6, Czech Republic $1 https://orcid.org/0000000159085182 $7 xx0068504
- 700 1_
- $a Křen, Vladimír $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 20 Prague 4, Czech Republic $1 https://orcid.org/0000000210914020 $7 xx0070803
- 700 1_
- $a Chytil, Petr $u Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského nám. 2, CZ-162 06 Prague 6, Czech Republic $1 https://orcid.org/0000000271359796
- 700 1_
- $a Bojarová, Pavla $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 20 Prague 4, Czech Republic $u Department of Health Care Disciplines and Population Protection, Faculty of Biomedical Engineering, Czech Technical University in Prague, nám. Sítná 3105, CZ-272 01 Kladno, Czech Republic $1 https://orcid.org/0000000170690973 $7 xx0122667
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 65, č. 5 (2022), s. 3866-3878
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35157467 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135426 $b ABA008
- 999 __
- $a ok $b bmc $g 1822696 $s 1170447
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 65 $c 5 $d 3866-3878 $e 20220214 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- LZP __
- $a Pubmed-20220720
